Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc., (“OBI”) (NASDAQ: OXBT), today announced enrollment of the first subject in the second cohort of its global Phase IIb clinical trial to investigate the safety and tolerability of Oxycyte® in patients with severe, non-penetrating traumatic brain injury (“STOP-TBI”). The first patient of the second cohort was enrolled in Israel at the Rambam Health Care Campus (RHCC) - the only Level 1 trauma center in the north of Israel. The RHCC’s neurotrauma center treats approximately 200 severe brain injuries annually and is recognized as a teaching center of excellence for the region. The neurotrauma center is led by Dr. Leon Levi who, together with Department of Neurosurgery Chief, Professor Menashe Zaaroor, serve as co-principal investigators in the STOP-TBI trial.
Help employers find you! Check out all the jobs and post your resume.
MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc., (“OBI”) (NASDAQ: OXBT), today announced enrollment of the first subject in the second cohort of its global Phase IIb clinical trial to investigate the safety and tolerability of Oxycyte® in patients with severe, non-penetrating traumatic brain injury (“STOP-TBI”). The first patient of the second cohort was enrolled in Israel at the Rambam Health Care Campus (RHCC) - the only Level 1 trauma center in the north of Israel. The RHCC’s neurotrauma center treats approximately 200 severe brain injuries annually and is recognized as a teaching center of excellence for the region. The neurotrauma center is led by Dr. Leon Levi who, together with Department of Neurosurgery Chief, Professor Menashe Zaaroor, serve as co-principal investigators in the STOP-TBI trial.
Help employers find you! Check out all the jobs and post your resume.
